Takeda-武田-2026-JPM.pdf

1、TSE:4502Takeda Pharmaceutical Company44th Annual J.P.Morgan Healthcare ConferencePresident&CEOJanuary 12th,2026Christophe WeberFor the purposes of this notice,“presentation”means this document,any oral presentation,any question and answer session and any written or oral material discussed or distrib

2、uted by Takeda Pharmaceutical Company Limited(“Takeda”)regarding this presentation.This presentation(including any oral briefing and any question-and-answer in connection with it)is not intended to,and does not constitute,represent or form part of any offer,invitation or solicitation of any offer to

3、 purchase,otherwise acquire,subscribe for,exchange,sell or otherwise dispose of,any securities or the solicitation of any vote or approval in any jurisdiction.No shares or other securities are being offered to the public by means of this presentation.No offering of securities shall be made in the Un

4、ited States except pursuant to registration under the U.S.Securities Act of 1933,as amended,or an exemption therefrom.This presentation is being given(together with any further information which may be provided to the recipient)on the condition that it is for use by the recipient for information pur

5、poses only(and not for the evaluation of any investment,acquisition,disposal or any other transaction).Any failure to comply with these restrictions may constitute a violation of applicable securities laws.The companies in which Takeda directly and indirectly owns investments are separate entities.I

6、n this presentation,“Takeda”is sometimes used for convenience where references are made to Takeda and its subsidiaries in general.Likewise,the words“we”,“us”and“our”are also used to refer to subsidiaries in general or to those who work for them.These expressions are also used where no useful purpose